Key result
Aripiprazole was identified as the cause of symptomatic bradycardia in a patient with bipolar disorder type I.
Why the study?
Atypical antipsychotics are widely used and have documented cardiac effects such as prolonged QT interval, but cardiac adverse effects warrant continued reporting.
Case Report (n=1)
This case highlights symptomatic bradycardia as a potential rare cardiac adverse effect of aripiprazole.
Alerts clinicians to possible aripiprazole-induced bradycardia; hypothesis-generating case report requiring validation in larger studies.
It is well known that typical antipsychotic drugs have been implicated as a cause of ventricular arrhythmias and cardiac arrest; studies have shown that conventional antipsychotics increase the risk of hospitalization for ventricular arrhythmias or cardiac arrest nearly 2-fold. However, atypical antipsychotics are not associated with an increased risk of hospitalization for ventricular arrhythmias or cardiac arrest. The use of atypical antipsychotics increased since they were first discovered and now are the mainstay of treatment, but with their broad use, heart effects have been documented, such as prolonged QT interval. Clozapine has been linked to severe cardiac problems, and risperidone has been linked to an increased risk of ventricular arrhythmias and cardiac arrest. We present a case of a patient with bipolar disorder who presented with symptomatic bradycardia secondary to aripiprazole.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2022) conducted a case report in Bipolar disorder type I (n=1). Aripiprazole was evaluated on Symptomatic bradycardia. Aripiprazole was identified as the cause of symptomatic bradycardia in a patient with bipolar disorder type I.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: